SCHEMBL1734549

SCHEMBL1734549

O=C[C@@H]1CCc2cc(F)ccc2O1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 2/20 0.51
DRD2 P14416 2/20 0.51
HTR2A P28223 2/20 0.51
MLNR O43193 1/20 0.51
ADRB2 P07550 1/20 0.51
ADRB1 P08588 1/20 0.51
ADRA2A P08913 1/20 0.51
ADORA3 P0DMS8 1/20 0.51
CHRM1 P11229 1/20 0.51
KCNE1 P15382 1/20 0.51
ADRA2B P18089 1/20 0.51
ADRA2C P18825 1/20 0.51
CNR1 P21554 1/20 0.51
SLC6A2 P23975 1/20 0.51
NPY1R P25929 1/20 0.51
HTR2C P28335 1/20 0.51
AVPR2 P30518 1/20 0.51
SLC6A4 P31645 1/20 0.51
ADRA1A P35348 1/20 0.51
OPRM1 P35372 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6846721 1.00 HTR1A (0.51) HTR1ADRD2HTR2AMLNRADRB2
SCHEMBL12435372 1.00 HTR1A (0.51) HTR1ADRD2HTR2AMLNRADRB2
SCHEMBL1734551 1.00 HTR1A (0.51) HTR1ADRD2HTR2AMLNRADRB2
SCHEMBL10510209 0.81 CYP4F2 (0.36) HTR1ADRD2HTR2AMLNRADRB2
SCHEMBL8864150 0.81 ESR1 (0.36) HTR1ADRD2HTR2AMLNRADRB2
SCHEMBL27849144 0.81 ESR1 (0.56) DRD2DRD3OPRK1ESR1ESR2
SCHEMBL22613778 0.81 ESR1 (0.39) HTR1ADRD2HTR2AMLNRADRB2
SCHEMBL27675947 0.79 DRD2 (0.44) HTR1ADRD2HTR2AMLNRADRB2
SCHEMBL10510220 0.78 DRD2 (0.37) HTR1ADRD2HTR2AMLNRADRB2
SCHEMBL10506849 0.77 DRD2 (0.43) DRD2DRD3HRH3SRD5A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101020685-A Synthesis process of 6-fluoro-3,4-dihydro-2H-1-benzopyran-2-epoxy ethane UNIV ZHEJIANG (CN) 2007-08-22 CN claimed
WO-2016185492-A1 PROCESS FOR PREPARATION OF NEBIVOLOL AND IT'S SALTS IPCA LABORATORIES LIMITED (IN) 2016-11-24 WO disclosed
EP-2646426-B1 Process for the preparation of nebivolol MENARINI INT OPERATIONS LU SA (LU) 2015-10-07 EP disclosed
US-9090922-B2 Process for the preparation of nebivolol MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A. (LU) 2015-07-28 US disclosed
US-9090922-B2 Process for the preparation of nebivolol MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A. (LU) 2015-07-28 US disclosed
US-8969597-B2 Process for preparing nebivolol ZACH SYSTEM S.P.A. (IT) 2015-03-03 US disclosed
US-8969597-B2 Process for preparing nebivolol ZACH SYSTEM S.P.A. (IT) 2015-03-03 US disclosed
EP-2328883-B1 METHOD FOR PREPARING NEBIVOLOL ZACH SYSTEM (FR) 2014-08-06 EP disclosed
US-20130295622-A1 PROCESS FOR THE PREPARATION OF NEBIVOLOL MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A. (LU) 2013-11-07 US disclosed
US-20130295622-A1 PROCESS FOR THE PREPARATION OF NEBIVOLOL MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A. (LU) 2013-11-07 US disclosed
US-20110021793-A1 PROCESS FOR PREPARING NEBIVOLOL ZACH SYSTEM S.P.A. (IT) 2011-01-27 US disclosed
US-20100069652-A1 The Process for Preparing Nebivolol ZACH SYSTEM S.P.A. (IT) 2010-03-18 US disclosed
US-20100069652-A1 The Process for Preparing Nebivolol ZACH SYSTEM S.P.A. (IT) 2010-03-18 US disclosed
EP-2163551-A1 An improved process for the preparation of nebivolol hydrochloride Cadila Pharmaceuticals Ltd. (IN) 2010-03-17 EP disclosed
WO-2009121710-A2 PROCESS FOR PREPARING NEBIVOLOL ZACH SYSTEM S.P.A. (IT) 2009-10-08 WO disclosed
WO-2008040528-A2 PROCESS FOR PREPARING NEBIVOLOL ZACH SYSTEM S.P.A. (IT) 2008-04-10 WO disclosed
CN-101020685-A Synthesis process of 6-fluoro-3,4-dihydro-2H-1-benzopyran-2-epoxy ethane UNIV ZHEJIANG (CN) 2007-08-22 CN disclosed
US-6545040-B1 Method of lowering the blood pressure JANSSEN PHARMACEUTICA N.V. (BE) 2003-04-08 US disclosed
EP-0334429-B1 AGENTS FOR LOWERING THE BLOOD PRESSURE JANSSEN PHARMACEUTICA N.V. (BE) 1992-11-19 EP disclosed
EP-0334429-A1 Agents for lowering the blood pressure JANSSEN PHARMACEUTICA N.V. (BE) 1989-09-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069652-A1 The Process for Preparing Nebivolol CYP4A11, ADRB1, CYP4B1 HTR1A 290/4885DRD2 377/4885HTR2A 743/4885
US-20110021793-A1 PROCESS FOR PREPARING NEBIVOLOL ADRB1, ADRA2B, ADRA1B HTR1A 1001/4885DRD2 181/4885HTR2A 1787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.